BGI Genomics Co., Ltd. (300676.SZ)
CNY 48.27
(1.3%)
CNY 48.27
(1.3%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 714.86 Million CNY | -63.46% |
| 2022 | 1.56 Billion CNY | -11.51% |
| 2021 | 2.13 Billion CNY | -22.73% |
| 2020 | 2.76 Billion CNY | 358.72% |
| 2019 | 600.68 Million CNY | -7.98% |
| 2018 | 671.97 Million CNY | 11.89% |
| 2017 | 636.58 Million CNY | 19.63% |
| 2016 | 527.55 Million CNY | 21.23% |
| 2015 | 432.78 Million CNY | 159.49% |
| 2014 | 180.46 Million CNY | -33.73% |
| 2013 | 259.65 Million CNY | 78.4% |
| 2012 | 145.12 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 132.38 Million CNY | 68.01% |
| 2024 Q3 | -142.52 Million CNY | -182.25% |
| 2024 Q1 | 63.77 Million CNY | -48.73% |
| 2023 Q3 | 91.34 Million CNY | 36.85% |
| 2023 FY | - CNY | -63.46% |
| 2023 Q1 | 65.92 Million CNY | -89.11% |
| 2023 Q2 | 66.74 Million CNY | 1.25% |
| 2023 Q4 | 110.93 Million CNY | 21.45% |
| 2022 FY | - CNY | -11.51% |
| 2022 Q4 | 605.14 Million CNY | 190.52% |
| 2022 Q3 | 208.29 Million CNY | -48.91% |
| 2022 Q2 | 407.66 Million CNY | -6.94% |
| 2022 Q1 | 438.07 Million CNY | 73.98% |
| 2021 Q2 | 715.98 Million CNY | 3.6% |
| 2021 Q4 | 251.8 Million CNY | -29.55% |
| 2021 FY | - CNY | -22.73% |
| 2021 Q3 | 357.43 Million CNY | -50.08% |
| 2021 Q1 | 691.07 Million CNY | 210.28% |
| 2020 FY | - CNY | 358.72% |
| 2020 Q1 | 178.86 Million CNY | 687.36% |
| 2020 Q2 | 1.93 Billion CNY | 980.16% |
| 2020 Q3 | 1.32 Billion CNY | -31.67% |
| 2020 Q4 | -626.65 Million CNY | -147.47% |
| 2019 Q4 | -30.45 Million CNY | -125.48% |
| 2019 FY | - CNY | -7.98% |
| 2019 Q3 | 119.52 Million CNY | -25.37% |
| 2019 Q2 | 160.15 Million CNY | 25.92% |
| 2019 Q1 | 127.18 Million CNY | 11.71% |
| 2018 FY | - CNY | 11.89% |
| 2018 Q1 | 133.74 Million CNY | 16.73% |
| 2018 Q2 | 160.6 Million CNY | 20.08% |
| 2018 Q3 | 154.65 Million CNY | -3.7% |
| 2018 Q4 | 113.85 Million CNY | -26.38% |
| 2017 Q1 | 145.34 Million CNY | 22.97% |
| 2017 Q2 | 175.85 Million CNY | 20.99% |
| 2017 Q3 | 145.76 Million CNY | -17.11% |
| 2017 Q4 | 114.57 Million CNY | -21.4% |
| 2017 FY | - CNY | 19.63% |
| 2016 FY | - CNY | 21.23% |
| 2016 Q4 | 118.19 Million CNY | 14.81% |
| 2016 Q3 | 102.95 Million CNY | -41.17% |
| 2016 Q2 | 175 Million CNY | 66.69% |
| 2016 Q1 | 104.98 Million CNY | 0.0% |
| 2015 FY | - CNY | 159.49% |
| 2015 Q1 | 59.62 Million CNY | 0.0% |
| 2015 Q2 | 59.62 Million CNY | 0.0% |
| 2014 FY | - CNY | -33.73% |
| 2013 FY | - CNY | 78.4% |
| 2012 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.86 Billion CNY | 61.571% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.84 Billion CNY | 74.886% |
| Dirui Industrial Co.,Ltd. | 288.83 Million CNY | -147.496% |
| Beijing Strong Biotechnologies, Inc. | 697.99 Million CNY | -2.417% |
| Medicalsystem Biotechnology Co., Ltd. | 475.01 Million CNY | -50.493% |
| Maccura Biotechnology Co.Ltd | 651.98 Million CNY | -9.644% |
| Guangzhou Wondfo Biotech Co.,Ltd | 859.12 Million CNY | 16.792% |
| Guangdong Hybribio Biotech Co.,Ltd. | 236.08 Million CNY | -202.802% |
| Amoy Diagnostics Co., Ltd. | 352.59 Million CNY | -102.742% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -59 Million CNY | 1311.442% |